NCT06390904View on ClinicalTrials.gov

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2027

Conditions
Atypical Endometrial HyperplasiaProgesterone ResistanceObesity
Interventions
DRUG

GnRH antagonist

Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.

DRUG

Letrozole 2.5mg

2.5mg po qd.

Trial Locations (2)

Unknown

Tenth People's Hospital of Tongji University, Shanghai

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Xiaojun Chen

OTHER